StockNews.com Upgrades Danaher (NYSE:DHR) to “Buy”

Danaher (NYSE:DHR) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Wednesday.

Several other equities analysts have also issued reports on the company. Stephens reissued an “overweight” rating and issued a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. TD Cowen upped their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Royal Bank of Canada lowered their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. UBS Group lowered their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Finally, KeyCorp upped their target price on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Trading Up 1.0 %

DHR traded up $2.32 during trading on Wednesday, hitting $238.90. The company’s stock had a trading volume of 2,271,416 shares, compared to its average volume of 2,764,883. Danaher has a twelve month low of $215.68 and a twelve month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The stock’s fifty day moving average price is $256.00 and its 200-day moving average price is $259.66. The firm has a market capitalization of $172.55 billion, a P/E ratio of 45.59, a PEG ratio of 4.37 and a beta of 0.85.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the firm earned $2.02 earnings per share. The company’s revenue was up 3.1% compared to the same quarter last year. Analysts anticipate that Danaher will post 7.5 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of DHR. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher during the 2nd quarter worth $25,000. nVerses Capital LLC bought a new position in shares of Danaher during the 2nd quarter worth $25,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher during the 3rd quarter worth $39,000. MidAtlantic Capital Management Inc. bought a new position in shares of Danaher during the 3rd quarter worth $40,000. Finally, FSA Wealth Management LLC bought a new position in shares of Danaher during the 3rd quarter worth $50,000. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.